Navigation Links
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Date:11/23/2008

DALLAS Nov. 23, 2008 Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

In a study appearing in the December issue of Nature Medicine, groups of guinea pigs infected with a virus similar to Lassa fever virus recovered from the fatal disease when treated with bavituximab alone or in combination with a common anti-viral medication. Bavituximab treatment also cured mice infected with cytomegalovirus, an opportunistic infection that afflicts transplant and AIDS patients.

Dr. Philip Thorpe, professor of pharmacology at UT Southwestern and senior author of the study, proposed that phosphatidylserine, a lipid molecule that is normally positioned on the internal surface of a cell, flips to the outside of the cell when the cell is infected by a virus. His laboratory developed bavituximab, which binds to phosphatidylserine on the infected cells. Dr. Thorpe, holder of the Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology, predicted that this interaction would muster the body's immune cells to attack and destroy the infected cells before the virus has a chance to replicate.

"When injected into the bloodstream, bavituximab circulates in the body until it finds these inside-out lipids and then binds to them," said Dr. Thorpe. "In the case of virus infection, the binding raises a red flag to the body's immune system, forcing the deployment of defensive white blood cells to attack the infected cells."

In the study, half of the guinea pigs infected with a virus similar to the Lassa fever virus were cured when bavituximab was administered alone. This is the first report of a therapeutic treatment being effective against advanced Lassa-like fever infections in animals. Lassa fever is an endemic disease in portions of West Africa, where the Lassa virus is carried by rats. As a hemor
'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Cancer requires support from immune system to develop, UT Southwestern researchers report
2. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
3. Steroids aid recovery from pneumonia, UT Southwestern researchers say
4. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
5. UT Southwestern scientists discover leptin can also aid type 1 diabetics
6. Tiny molecule helps control blood-vessel development, UT Southwestern researchers find
7. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
8. UT Southwestern: Hidden facial cheek fat compartments are key to youthful appearance
9. UT Southwestern surgeons complete first single-incision lap-band surgery in Texas
10. Fireflies glow helps UT Southwestern researchers track cancer drugs effectiveness
11. UT Southwestern faculty members named Howard Hughes investigators

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--AnarticlebyJanetW...tionandResearch,titled"ADifficultBalance-PainManag...9issueofTheNewEnglandJournalofMedicine. ,, (Log...ALOGO ) ,, Inthearticle,WoodcockdiscussesFDAeff...orthosewhoneeditandmanagingtherisksposedbyvariousa...
(Date:11/25/2009)...Endorsements,Business,andPressJoinEfforttoEducate ...--Onceagain,theNationalBipolarFoundationandtheMedi..."Safe,tilStable"program,whichisnowbeingwidelyaccep...r.Today,theNationalBipolarFoundationreceivedaprocl...romtheLt.GovernorofLouisianaMitchLandrieu.TheNatio...
(Date:11/25/2009)...ery that grew out of a collaboration between UCLA ...ope to the nearly 10 million Americans who suffer ...wn as hardening of the arteries, peripheral arteri...m in which narrowed arteries reduce blood flow to ...for vascular disease, heart attack and stroke, and...
(Date:11/25/2009)... to fight rheumatoid arthritis, could help newly d...ESDAY, Nov. 25 (HealthDay News) -- A drug commonly...id arthritis now also shows some promise in helpin..., The drug, rituximab (Rituxan), helped patients...ough the disease had destroyed some of their pancr...
(Date:11/25/2009)... by neurological symptoms, study finds , ...gical side effects are among the potential problem...r who were treated with cisplatin-based chemothera... 1,409 Norwegian men treated for unilateral testic... a follow-up survey conducted from 1998 to 2002. ,...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
... by the researchers now reckons the evil effects o... protects against the development of brain tumors ...s done a couple of years ago , an unexpected findi...// The recent study undwells the fact that g...
...al engineering team has announced the development ... person,with an ability to deliver a visual acuity...ature television camera and an ultrasonic distance... processing the video and distance signals,// the ...
...ng history of sorts, doctors in Ohio, the United S...ar vein to a man to rid him of a painful ulcer due...his is the first time a bovine vein is used in man...ceeded very well. Dr. Hugh Beebe, the center's dir...
...chers at the Georgetown University Lombardi cancer...a protein that they say, is responsible for the sp...lled Pa 28 alpha, can also cause the spread of oth... To isolate the protein, Ngaiza and colleagues ...
...test in cardiology is OCT, which expands into Opti...de many cardiologists sit up and take notice and i...oped by Dr. Brett Bouma an assistant professor at ...ound and will allow cardiologists to view the stat...
...reakthrough using gene therapy mouthwash promises ...hwash wards off oral cancer by destroying suspicio...nt. The idea is to attack the pre-cancerous patche...nthusiastic, as the patches have disappeared compl...
Other Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...ery-USMarketTrends&Analysis http://www.report...Market-Trends--Analysis.html ,, TheUSintranasa...euticapplicationsfromthedeliveryofconventionalloca...cdrugs.Thefutureofthetechnologyhingesontotheeffect...
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 1EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 3Statewide program to improve emergency care for children 54567 1Statewide program to improve emergency care for children 54567 2Scientists take early steps toward mapping epigenetic variability 9583 1Scientists take early steps toward mapping epigenetic variability 9583 2
...udy to Show That Extended,Thromboprophylaxis Reduc... Statistically Significant 44% , PARIS, July 8, 20...ed today the results of the EXCLAIM (EXtended CLin...study, which showed,the benefit of extended prophy... mobility by demonstrating the superiority of 5 we...
...Inc. (NASDAQ:INSM), a ,biopharmaceutical company f...r the treatment of metabolic diseases with unmet,...nt at this,week,s C.E. Unterberg, Towbin (CEUT) Em... City. , The conference, to be held at the Mand...om Tuesday, July 10th through Thursday,July 12th....
Other Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
Ultimum Introducers
Irrigating Cannula Handpiece (Titanium)
Stronger Irrigation/Aspiration Cannula
... are designed for endomyocardial biopsies. The r... of a 3-pull ring handle, stainless steel cutting ...rotates to accommodate any position. ,A spring in...s are opened by moving the double rings away from ...
Medicine Products: